Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

1.

Neopterin as a marker of response to antiviral therapy in hepatitis C virus patients.

Oxenkrug GF, Requintina PJ, Mikolich DL, Ruthazer R, Viveiros K, Lee H, Summergrad P.

Hepat Res Treat. 2012;2012:619609. doi: 10.1155/2012/619609. Epub 2012 Jun 28.

PMID:
22811898
[PubMed]
Free PMC Article
2.
3.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

PMID:
15461877
[PubMed - indexed for MEDLINE]
Free Article
4.

Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.

Braga EL, Lyra AC, Nascimento L, Netto E, Kalabrik L, Lyra LG.

Arq Gastroenterol. 2006 Oct-Dec;43(4):275-9.

PMID:
17406754
[PubMed - indexed for MEDLINE]
Free Article
6.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
[PubMed - indexed for MEDLINE]
7.

[Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].

Pár A, Tornai I, Szalay F.

Orv Hetil. 2007 May 6;148(18):819-26. Hungarian.

PMID:
17468063
[PubMed - indexed for MEDLINE]
8.

IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.

Reiberger T, Aberle JH, Kundi M, Kohrgruber N, Rieger A, Gangl A, Holzmann H, Peck-Radosavljevic M.

Antivir Ther. 2008;13(8):969-76.

PMID:
19195322
[PubMed - indexed for MEDLINE]
9.
10.

Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.

Bizollon T, Adham M, Pradat P, Chevallier M, Ducerf C, Baulieux J, Zoulim F, Trepo C.

Transplantation. 2005 Feb 15;79(3):325-9.

PMID:
15699763
[PubMed - indexed for MEDLINE]
11.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
[PubMed - indexed for MEDLINE]
12.

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence.

Sharma P, Marrero JA, Fontana RJ, Greenson JK, Conjeevaram H, Su GL, Askari F, Sullivan P, Lok AS.

Liver Transpl. 2007 Aug;13(8):1100-8.

PMID:
17377914
[PubMed - indexed for MEDLINE]
Free Article
13.

Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.

Merli M, Giannelli V, Gentili F, Giusto M, Simmaco M, Lionetto L, Corradini SG, Biliotti E, Attili AF, Rossi M, Taliani G.

Antivir Ther. 2011;16(6):879-85. doi: 10.3851/IMP1834.

PMID:
21900720
[PubMed - indexed for MEDLINE]
14.

Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing.

Neff GW, O'Brien CB, Cirocco R, Montalbano M, de Medina M, Ruiz P, Khaled AS, Bejarano PA, Safdar K, Hill MA, Tzakis AG, Schiff ER.

Liver Transpl. 2004 May;10(5):595-8.

PMID:
15108250
[PubMed - indexed for MEDLINE]
Free Article
15.

Enhancing the response to interferon-alpha.

Begemann F, Jablonowski H.

J Clin Virol. 1999 Jun;13(1-2):1-7.

PMID:
10405886
[PubMed - indexed for MEDLINE]
16.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
[PubMed - indexed for MEDLINE]
17.

Chronic hepatitis C virus infection in renal transplant: treatment and outcome.

Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.

Clin Transplant. 2006 Nov-Dec;20(6):677-83.

PMID:
17100715
[PubMed - indexed for MEDLINE]
18.

Predicting the probable outcome of treatment in HCV patients.

Navaneethan U, Kemmer N, Neff GW.

Therap Adv Gastroenterol. 2009 Sep;2(5):287-302. doi: 10.1177/1756283X09339079.

PMID:
21180557
[PubMed]
Free PMC Article
19.

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

Teuber G, Berg T, Hoffmann RM, Leifeld L, Lafrenz M, Spengler U, Pape GR, Hopf U, Zeuzem S.

Digestion. 2000;61(2):90-7.

PMID:
10705172
[PubMed - indexed for MEDLINE]
20.

Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.

Aziz H, Gil ML, Waheed Y, Adeeb U, Raza A, Bilal I, Athar MA.

Infect Genet Evol. 2011 Apr;11(3):640-5. doi: 10.1016/j.meegid.2011.01.022. Epub 2011 Feb 18.

PMID:
21316487
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk